专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1253948A2 GENE THERAPY FOR TREATING OCULAR-RELATED DISORDERS 审中-公开
标题翻译：基因治疗眼睛投诉处理
公开(公告)号：EP1253948A2
公开(公告)日：2002-11-06
申请号：EP01909022.4
申请日：2001-02-09
申请人： GENVEC, INC.
发明人： KOVESDI, Imre , BROUGH, Douglas, E. , MCVEY, Duncan, L. , WEI, Lisa
IPC分类号： A61K48/00
CPC分类号： A61K48/0075 , A61K48/005 , C07K14/71 , C07K14/811 , C12N15/86 , C12N2710/10343
摘要： The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.

2. 发明公开

EP1649028A2 ADENOVIRAL VECTOR-BASED VACCINES 有权
标题翻译：腺病毒载体，为基础的疫苗
公开(公告)号：EP1649028A2
公开(公告)日：2006-04-26
申请号：EP04779179.3
申请日：2004-07-26
申请人： GENVEC, INC.
发明人： GALL, Jason G. D. , WICKHAM, Thomas J. , ENRIGHT, William, J. , BROUGH, Douglas, E. , ZUBER, Mohammed , KING, C., Richter
IPC分类号： C12N15/861 , A61K39/235
CPC分类号： C12N15/86 , A61K48/00 , A61K2039/5256 , C07K2319/00 , C12N2710/10343 , C12N2710/10345
摘要： The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal a non-subgroup C adenoviral vector comprising an adenoviral fiber protein having an amino acid sequence comprising about 80 % or more identity to an amino acid sequence encoding a subgroup C adenoviral fiber protein. The adenoviral vector further comprises a nucleic acid sequence encoding an antigen which is expressed in the mammal to induce an immune response. The invention further comprises a method of producing an adenoviral vector, and a composition comprising a serotype 41 or a serotype 35 adenoviral vector and a carrier. The invention also provides an adenoviral vector comprising a nucleic acid sequence encoding an adenoviral pIX protein operably linked to a heterologous expression control sequence, as well as a method of enhancing the stability and/or packaging capacity of an adenoviral vector.

3. 发明授权

EP1294918B1 REPLICATION DEFICIENT ADENOVIRAL TNF VECTOR 有权
标题翻译：复制缺陷的腺病毒TNF载体
公开(公告)号：EP1294918B1
公开(公告)日：2005-10-12
申请号：EP01950575.9
申请日：2001-06-27
申请人： GenVec, Inc.
发明人： BROUGH, Douglas, E. , KING, C., Richter , KOVESDI, Imre
IPC分类号： C12N15/861 , C12N15/28 , C07K14/525 , C12N5/10 , C12N7/01 , A61K48/00
CPC分类号： C12N15/86 , A61K38/191 , A61K48/00 , C12N2710/10343 , C12N2810/40
摘要： An adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a radiation inducible promoter operably linked to the nucleic acid sequence coding for TNF. This invention also provides an adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a spacer element of at least 15 base pairs in the E4 region of the adenoviral genome. A method of producing an adenoviral vector and a method of treating a tumor or cancer in a host comprising administering an anti-cancer or anti-tumor effective amount of the adenoviral vector of the present invention also is provided.

4. 发明授权

EP0996735B1 CHIMERIC VECTORS COMPRISING A PHAGE PACKAGING SITE AND A PORTION DERIVED FROM THE GENOME OF A EUKARYOTIC VIRUS 失效
标题翻译：嵌合载体包含的区域PHAG基因组的真核细胞病毒基因组的包装和PART
公开(公告)号：EP0996735B1
公开(公告)日：2003-12-10
申请号：EP98929010.1
申请日：1998-06-09
申请人： GENVEC, INC.
发明人： McVEY, Duncan, L. , BROUGH, Douglas, E. , ZUBER, Mohammed , KOVESDI, Imre
IPC分类号： C12N15/86 , C12N7/01
CPC分类号： C12N15/86 , C12N2710/10343 , C12N2710/10344 , C12N2795/10344 , C12N2810/405 , C12N2830/002 , C12N2830/005 , C12N2830/15 , C12N2830/55
摘要： The present invention provides an improved method of making eukaryotic gene transfer vectors comprising homologous recombining lambdid vectors with a second DNA in a bacterium to generate recombinant eukaryotic viral gene transfer vectors as well as lambdid vector used in the inventive method and an inventive system comprising the lambdid vector.

5. 发明公开

EP1088092A1 REPLICATION-DEFECTIVE RECOMBINANT ADENOVIRUS WITH MUTATED MAJOR LATE PROMOTER 审中-公开
标题翻译：复制缺陷型腺病毒主要晚期启动子修饰
公开(公告)号：EP1088092A1
公开(公告)日：2001-04-04
申请号：EP99930675.6
申请日：1999-06-24
申请人： GENVEC, INC.
发明人： BROUGH, Douglas, E. , KOVESDI, Imre
IPC分类号： C12N15/86 , C12N5/10 , A61K39/235 , A61K48/00
CPC分类号： C12N15/86 , A61K48/00 , C12N2710/10343
摘要： The present invention provides a recombinant adenovirus having a genome with a deficiency in the E1 region and a mutation in the MLP. The invention also provides stocks of such viruses and compositions including the inventive viruses. The invention also provides cell lines for propagating the recombinant adenoviruses.

6. 发明公开

EP0863987A2 VECTORS AND METHODS FOR GENE TRANSFER TO CELLS 失效
标题翻译：向量和在细胞中的基因转移方法
公开(公告)号：EP0863987A2
公开(公告)日：1998-09-16
申请号：EP96940927.0
申请日：1996-11-27
申请人： GENVEC, INC.
发明人： WICKHAM, Thomas, J. , KOVESDI, Imre , BROUGH, Douglas, E.
IPC分类号： C12N15 , A61K48 , C07K14 , C07K19 , C12N5 , C12N7 , A61K38 , C12R1
CPC分类号： C12N15/86 , A61K48/00 , C07K14/005 , C07K2319/00 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12N2810/40 , C12N2810/405 , C12N2810/60
摘要： The present invention provides a chimeric adenovirus coat protein, which differs from the wild-type coat protein by the introduction of a nonnative amino acid sequence. Such a chimeric adenovirus coat protein according to the invention is able to direct entry into cells of a vector comprising the coat protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus coat protein rather than the chimeric adenovirus coat protein. The chimeric coat protein preferably is a fiber, hexon, or penton protein. The present invention also provides an adenoviral vector that comprises the chimeric adenovirus coat protein, as well as methods of constructing and using such a vector.

7. 发明公开

EP2654786A1 ADENOVIRAL VECTOR-BASED DENGUE FEVER VACCINE 失效转让
标题翻译： ON腺病毒载体基于登革热疫苗
公开(公告)号：EP2654786A1
公开(公告)日：2013-10-30
申请号：EP11804904.8
申请日：2011-12-20
申请人： GenVec, Inc.
发明人： BRUDER, Joseph, T. , MCVEY, Duncan , BROUGH, Douglas, E.
IPC分类号： A61K39/12 , A61K39/295 , C07K14/075 , C07K14/18 , C12N15/861
CPC分类号： A61K39/12 , A61K2039/5256 , C07K14/005 , C07K2319/00 , C07K2319/40 , C12N15/86 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12N2770/24134 , C12N2810/6018 , Y02A50/386
摘要： The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.

8. 发明授权

EP1135515B1 USE OF TRANS-ACTIVATION AND CIS-ACTIVATION TO MODULATE THE PERSISTENCE OF EXPRESSION OF A TRANSGENE 有权
标题翻译：反式激活和独联体活化TRANS的基因表达的持续时间调制
公开(公告)号：EP1135515B1
公开(公告)日：2006-05-17
申请号：EP99964075.8
申请日：1999-12-03
申请人： GENVEC, INC.
发明人： BROUGH, Douglas, E. , KOVESDI, Imre
IPC分类号： C12N15/861 , C12N15/35 , C12N15/38 , C07K14/035 , C07K14/075 , C12N15/63
CPC分类号： C12N15/86 , C07K14/005 , C12N15/63 , C12N2710/10322 , C12N2710/10345 , C12N2710/16622 , C12N2830/60 , C12N2840/60
摘要： Provided are methods of modulating the persistence of the expression in a cell of a transgene, such as a transgene in a non-Herpes vector or in at least E4Δ adenoviral vector, and related systems. One method comprises contacting the cell with a non-Herpes vector comprising and expressing a gene encoding HSV ICP0, whereupon expression of HSV ICP0 the persistence of expression of the transgene is modulated. Further provided is a system for modulating the persistence of expression of a transgene, which system comprises a non-Herpes vector comprising (i) a gene encoding HSV ICP0 and (ii) a transgene, wherein the HSV ICP0 modulates the persistence of expression of the transgene and either the non-Herpes vector comprises the transgene or the system further comprises a vector, in which case the vector comprises the transgene. Another method comprises contacting the cell with an at least E4Δ adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, wherein the trans-acting factor modulates the persistence of expression of the transgene and the gene encoding the trans-acting factor is not from the E4 region of an adenovirus. Yet another method comprises contacting a cell simultaneously or sequentially with (i) an at least E4Δ adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. Also provided is a system for modulating the persistence of expression of a transgene in an at least E4Δ adenoviral vector, which system comprises (i) an at least E4Δ adenoviral vector comprising a transgene and (ii) a gene encoding a trans-acting factor, wherein the gene encoding the trans-acting factor is not from the E4 region of an adenovirus, the trans-acting factor modulates the persistence of expression of the transgene, and either the at least E4Δ adenoviral vector comprises the gene encoding the trans-acting factor or the system comprises a viral vector, in which case the viral vector comprises the gene encoding the trans-acting factor.

9. 发明授权

EP0870049B1 COMPLEMENTARY ADENOVIRAL VECTOR SYSTEMS AND CELL LINES 失效
标题翻译：互补ADENOVIRENVEKTORSYSTEME及细胞系
公开(公告)号：EP0870049B1
公开(公告)日：2006-03-15
申请号：EP96944346.4
申请日：1996-12-12
申请人： GENVEC, INC.
发明人： KOVESDI, Imre , BROUGH, Douglas, E. , MCVEY, Duncan, L. , BRUDER, Joseph, T. , LIZONOVA, Alena
IPC分类号： C12N15/86 , A61K48/00 , C12N5/10 , G01N33/50
CPC分类号： C12N15/86 , A61K38/00 , A61K48/00 , A61K2039/5256 , C07K14/005 , C07K14/4712 , C12N7/00 , C12N2710/10322 , C12N2710/10343 , C12N2710/10352 , C12N2800/108 , C12N2810/60 , C12N2810/6081 , C12N2830/002 , C12N2830/85 , C12N2840/20 , C12N2840/203 , C12N2840/44
摘要： The present invention provides multiply replication deficient adenoviral vectors having a spacer in at least one replication deficient adenoviral region, as well as complementing cell lines therefor. Also provided are means of constructing the multiply replication deficient adenoviral vectors and methods of use thereof, e.g., in gene therapy.

10. 发明公开

EP1294918A2 REPLICATION DEFICIENT ADENOVIRAL TNF VECTOR 有权
标题翻译： REPLIKATIONSDEFIZIENTER ADENOVIRALER TNF VEKTOR
公开(公告)号：EP1294918A2
公开(公告)日：2003-03-26
申请号：EP01950575.9
申请日：2001-06-27
申请人： GENVEC, INC.
发明人： BROUGH, Douglas, E. , KING, C., Richter , KOVESDI, Imre
IPC分类号： C12N15/861 , C12N15/28 , C07K14/525 , C12N5/10 , C12N7/01 , A61K48/00
CPC分类号： C12N15/86 , A61K38/191 , A61K48/00 , C12N2710/10343 , C12N2810/40
摘要： An adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a radiation inducible promoter operably linked to the nucleic acid sequence coding for TNF. This invention also provides an adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a spacer element of at least 15 base pairs in the E4 region of the adenoviral genome. A method of producing an adenoviral vector and a method of treating a tumor or cancer in a host comprising administering an anti-cancer or anti-tumor effective amount of the adenoviral vector of the present invention also is provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式